Phase I trial of Temodar [temozolomide] plus 06-benzylguanine (06-BG) (NSC 637037) in the treatment of patients with newly diagnosed (Part 1) or or recurrent/progressive (Parts 1 and 2) cerebral anaplastic gliomas.

Trial Profile

Phase I trial of Temodar [temozolomide] plus 06-benzylguanine (06-BG) (NSC 637037) in the treatment of patients with newly diagnosed (Part 1) or or recurrent/progressive (Parts 1 and 2) cerebral anaplastic gliomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2011

At a glance

  • Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 26 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top